Abstract Breast cancer is the second leading cancer among all types of cancers
Guideline Perspectives on Metformin in 2026 Leading organizations such as the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) still recommend metformin as a first-line agent for most people with type 2 diabetes
In a 104-week extension, patients reached 30.3%
Discussion should cover injection technique, adverse effect management, cost considerations (often $900-1,300 monthly without insurance coverage), and long-term treatment duration, as weight regain commonly occurs after discontinuation
First-generation copper peptides, second-generation SRCP formulations, various ratios of peptide to copper, synthetic versus naturally occurring variants, each designed for specific applications that most guides fail to distinguish